10X Genomics Inc TXG:NASDAQ

Last Price$45.72NASDAQ Previous Close - Last Trade as of 3:58PM ET 5/24/22

Today's Change-4.04(8.12%)
Bid (Size)$45.72 (120)
Ask (Size)$45.80 (3)
Day Low / High$45.22 - 48.75
Volume1.0 M

Read more news Recent News

Research Alert: CFRA Keeps Buy Opinion On Shares Of 10x Genomics
4:10PM ET 5/05/2022 MT Newswires

CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as...

--Citigroup Adjusts 10x Genomics' Price Target to $100 from $150, Keeps Buy Rating
12:39PM ET 5/05/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

-- Earnings Flash (TXG) 10X GENOMICS Posts Q1 Loss $-0.38, vs. Street Est of $-0.34
4:45PM ET 5/04/2022 MT Newswires


-- Earnings Flash (TXG) 10X GENOMICS Posts Q1 Revenue $114.5M, vs. Street Est of $113.3M
4:45PM ET 5/04/2022 MT Newswires


View all Commentary and Analysis

ShockWave Medical: The Next Edwards
12:59PM ET 5/11/2022 Seeking Alpha

10x Genomics, Inc. (TXG) CEO Serge Saxonov on Q1 2022 Results - Earnings Call Transcript
8:02PM ET 5/04/2022 Seeking Alpha

Let's Go Dumpster Diving
8:54AM ET 3/29/2022 Seeking Alpha

Why Has ARKK Dropped Over 30% This Year And Where Is It Headed?
9:30AM ET 3/11/2022 Seeking Alpha

Company Profile

Business Description
Number of EmployeesN/A
Recent SEC Filing05/17/20224

Company Highlights

Price Open$48.42
Previous Close$49.76
52 Week Range$36.76 - 208.99
Market Capitalization$4.3 B
Shares Outstanding93.9 M
SectorHealth Technology
Next Earnings Announcement08/03/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.80
Beta vs. S&P 500N/A
Net Profit Margin-17.85%
Return on Equity-11.10%

Analyst Ratings as of 11/08/2021

Consensus RecommendationConsensus Icon
Powered by Factset